Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

Based on the previously described roles of doxorubicin in immunogenic cell death, both doxorubicin and liposomal doxorubicin (Doxil) were evaluated for their ability to boost the antitumor response of different cancer immunotherapies including checkpoint blockers (anti–PD-L1, PD-1, and CTLA-4 mAbs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Rios-Doria, Jonathan, Durham, Nicholas, Wetzel, Leslie, Rothstein, Raymond, Chesebrough, Jon, Holoweckyj, Nicholas, Zhao, Wei, Leow, Ching Ching, Hollingsworth, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674486/
https://www.ncbi.nlm.nih.gov/pubmed/26408258
http://dx.doi.org/10.1016/j.neo.2015.08.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674486/
https://www.ncbi.nlm.nih.gov/pubmed/26408258
http://dx.doi.org/10.1016/j.neo.2015.08.004

Ejemplares similares